Best of ASCO - 2014 Annual Meeting



Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).

Lung Cancer - Non-Small Cell Metastatic

Lung Cancer - Non-Small Cell Metastatic

2014 ASCO Annual Meeting

Abstract No:

J Clin Oncol 32:5s, 2014 (suppl; abstr 8007)

Attend this session at the
2014 ASCO Annual Meeting!

Session: Lung Cancer - Non-small Cell Metastatic

Type: Oral Abstract Session

Time: Monday June 2, 3:00 PM to 6:00 PM

Location: E Hall D2

Personalize your Meeting experience with a suggested or customized itinerary!

Author(s): Naiyer A. Rizvi, Edward B. Garon, Amita Patnaik, Leena Gandhi, Natasha B. Leighl, Ani Sarkis Balmanoukian, Jonathan Wade Goldman, Joseph Paul Eder, Elizabeth Johnson, George R. Blumenschein, Matthew A. Gubens, Kyriakos P. Papadopoulos, Gregory M. Lubiniecki, Jin Zhang, Michelle Niewood, Kenneth Emancipator, Marisa Dolled-Filhart, Mary Elizabeth Hanson, Rina Hui; Memorial Sloan Kettering Cancer Center, New York, NY; University of California, Los Angeles, Los Angeles, CA; START Center for Cancer Care, San Antonio, TX; Dana-Farber Cancer Institute, Boston, MA; Princess Margaret Cancer Centre, Toronto, ON, Canada; The Angeles Clinic and Research Institute, Los Angeles, CA; David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; AstraZeneca, Waltham, MA; Mayo Clinic, Jacksonville, FL; Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; University of California, San Francisco, San Francisco, CA; Merck & Co., Inc., Whitehouse Station, NJ; Westmead Hospital, University of Sydney, Sydney, Australia

Abstract Disclosures


Background: Programmed death-1 (PD-1) receptor-ligand interaction inhibits T cell activation against tumor cells. MK-3475 is a potent and highly selective humanized monoclonal antibody against PD-1 designed to directly block its interaction with its ligands, PD-L1 and PD-L2, thus removing the inhibition of T cell activation against cancer. MK-3475 led to prolonged anti-tumor activity in previously treated NSCLC patients. This Phase I study evaluated the safety, tolerability, and clinical activity of MK-3475 as initial therapy in patients with locally advanced or metastatic NSCLC. Methods: Patients with no prior systemic therapy for metastatic disease whose tumors expressed PD-L1 by a preliminary immunohistochemical assay were randomized to MK-3475 10 mg/kg every 2 or 3 wks (Q3W). The first 11 patients were randomized to 2 mg/kg and 10 mg/kg Q3W. At least 1 measurable tumor lesion, ECOG performance status of 0 to 1, adequate organ function and adequate tumor biopsy were required for enrollment. Prior adjuvant therapy was allowed if it preceded relapse by at least a year. Tumor response was assessed every 9 weeks until confirmed disease progression per immune related response criteria (irRC; investigator review); RECIST 1.1 by independent central review will also be performed. Results: 84 patients submitted tissue for PD-L1 assessment and 57 patients had tumors that expressed PD-L1. Between Feb 2013 and Oct 2013, 45 patients started treatment (n=6 2Q3W, n=23 10Q3W, n=16 10Q2W). Preliminary data indicate an ORR (confirmed and unconfirmed) of 36% (67% 2 mg/kg Q3W, 27% 10 mg/kg Q3W, 35% 10 mg/kg Q2W) by irRC. 25 patients (55%), including all but 2 responders, remain on treatment (treatment duration from 12+ to 48+ wks). 52% of patients experienced a drug-related adverse event (AE), usually grade 1-2 in severity, most commonly fatigue (14%), pruritus (8%), dermatitis acneiform (6%), diarrhea (6%) and dyspnea (6%). There was a single drug-related grade 3-5 AE, a grade 3 pericardial effusion. Conclusions: These data suggest that MK-3475 is generally well-tolerated and provides robust antitumor activity in a first-line setting in patients with locally advanced or metastatic NSCLC that expresses PD-L1. Clinical trial information: NCT01295827.


  Other Abstracts in this Sub-Category:


1. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.

Meeting: 2014 ASCO Annual Meeting Abstract No: 8000 First Author: David R. Spigel
Category: Lung Cancer - Non-Small Cell Metastatic


2. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).

Meeting: 2014 ASCO Annual Meeting Abstract No: 8001 First Author: D. Ross Camidge
Category: Lung Cancer - Non-Small Cell Metastatic


3. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

Meeting: 2014 ASCO Annual Meeting Abstract No: 8002 First Author: Tony Mok
Category: Lung Cancer - Non-Small Cell Metastatic